Rationale for Treating Community-Acquired Lower Respiratory Tract Infections with Amoxicillin/Sulbactam Combination Through Pharmacodynamic Analysis in the Setting of Aminopenicillin-Resistant Organisms-Reference-Cited by-同舟云学术

Rationale for Treating Community-Acquired Lower Respiratory Tract Infections with Amoxicillin/Sulbactam Combination Through Pharmacodynamic Analysis in the Setting of Aminopenicillin-Resistant Organisms

Published:2001-01 Issue:4 Volume:13 Page:402-406
ISSN:1120-009X
Container-title:Journal of Chemotherapy
language:en
Short-container-title:Journal of Chemotherapy

Author:

Bantar C.,Nicola F.,Canigia L. Fernandez,Arenoso H.J.,Soutric J.,Montoto M.,Blanco M.,Smayevsky J.,Jasovich A.

Publisher

Informa UK Limited

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Oncology

Link

http://www.tandfonline.com/doi/pdf/10.1080/10256018808623883

Reference12 articles.

1. Prognosis and Outcomes of Patients With Community-Acquired Pneumonia

2. Outpatient Treatment of Community-Acquired Pneumonia in Adults

3. In Vitro Antibacterial Activity of a New Oral Cephalosporin, S-1090

4. State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updated Acute Community-Acquired Pneumonia in Adults: Guidelines for Initial Antimicrobial Therapy Based on Local Evidence from the South American Working Group (Consensur II);Current Respiratory Medicine Reviews;2010-05-01

2. Pharmacodynamic assessment of Amoxicillin-Sulbactam against Acinetobacter baumannii: searching the optimal dose and infusion time through a human ex-vivo model;Brazilian Journal of Infectious Diseases;2009-10

3. Intravenous Amoxicillin-Sulbactam againstEscherichia Coli: Optimizing the Dose, Component Ratio and Infusion Time Using a Human Pharmacodynamic Model;Journal of Chemotherapy;2009-06

4. Effect of sodium diclofenac on the bioavailability of amoxicillin;International Journal of Antimicrobial Agents;2006-05

5. Efficacy of Amoxicillin-Sulbactam, Given Twice-a-Day, for the Treatment of Community-Acquired Pneumonia: A Clinical Trial Based on a Pharmacodynamic Model;Journal of Chemotherapy;2002-01